So about the licensing agreement with Novartis...........

Any insights as to why the company is licensing Utibron, Seebri, and Arcapta from Novartis? I read in the press release that Arcapta has been on the market since 2012, and the others were approved in 2015. This market is crowded enough, with GSK and AZ getting the lion's share. In fact, AZ is just now launching their new glycopyrrolate/formoterol combo as we speak. WTF??

 

Desperate move by a dying company? Perhaps that could be the explanation? Latuda will be going off patent in a little over a year. The way this company axes entire sales forces about 9 months before patent expiration, I think we'll have a lot less sales reps here before the end of this year.

Latuda loss of exclusivity gives us a loss of over 1 billion dollars a year in gross. That leaves us with Brovana at about $220 million a year and Aptiom at about, well, geeze, I don't even know what Aptiom is doing a year in gross. About $100 million. If that! So we are going from a $1.52 billion dollar a year in sales company to a $320 million dollar a year in sales company within about a year and 2 months. You do the math Homer. We are trying to grasp at straws. SUN101 as Desotraline are joke products. How many of you think we will still have jobs here in January of 2018. I think about 65% of the sales force will be gone and the home office will be gutted. we'll go back to the days of tiny Sepracor trying to scrape for a few scraps.

 

Brovana will be generic by 2018 as well.

 

So will Aptiom! Cupboard will be bare late 2018 or early 2019.

Let that sink in a moment for those of you without an exit strategy--By the end of next year, all our currently marketed products will be gone..........

 

Brovana's patent is something like 2023 and Aptiom is something like 2030 you idiots.

 

Keep telling yourself that. Xopenex had patents until 2021 but the key word is enforceable. There is nothing enforceable about the Brovana or Aptiom patents past 2018. You can take that to the bank. Everything past that date is smoke and mirrors.

 

Yeah man he told you. Not enforceable! Get your facts straight!! You were out in a bodybag.

 

Xopenex: November 8, 2011
https://www.uspto.gov/sites/default/files/web/offices/pac/dapp/opla/term/certs/5362755.pdf
What else would you like to make up just to be an asshole?

 

Xopenex patent was to 2011

 

https://www.drugpatentwatch.com/p/tradename/XOPENEX

Some bogus patents, or unenforceable ones, are on until 2021. The scan you provided actually states that there is an extension of the '755 patent for 503 days after the normal Nov, 2011 patent. That would put it into mid 2013.

Drug companies always try to put a barbed wire fence around their products with numerous patents like the manufacturing process, labelling patents, and other things that might intimidate some generic houses with small legal staffs, but the Ranbaxys, Tevas, Mylans, and Dr. Reddy's of the world can work their way past them. Once the NCE patent is gone, the product becomes somewhat vulnerable. That is why companies wait till the last minute to get the pediatric indication to get a last 6 months exclusivity out of the product.

Brovana and Aptiom have no enforceable patents past 2018. Even if by the Sunovion miracle of increasing sales by increasing price the sales hit a combined $450 million by then, the company is still going to have to make up a billion by then, and in a crowded respiratory market market with many competitors like Advair and Symbicort going generic by then, there may be double or triple step edits to get through. Aption again. Dasotraline for binge eating in kids.........what do you think that market is worth. The drug already failed the clinical trial it was intended for. Oncology? When? Everything going to go smoothly and replace that $1 billion as fast as Latuda going generic is going to lose it? And if it does, they aren't going to hire you. They will go outside the company to look for experienced talent. Did it with Latuda, did it with Aptiom.